de

Registrieren
Investieren birgt Risiken und ist nicht für alle Anleger geeignet.

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Aktien・BioCryst Pharmaceuticals Inc
Search

BioCryst Pharmaceuticals Inc

Geschlossen

Branche Gesundheitswesen

7.83 3.71

Starkes Kaufsignal

Kursupdate 26. Juli 2024, 19:59 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.52

Max

7.84

Schlüsselkennzahlen

By Trading Economics

Einkommen

-36M

Verkäufe

6.7M

93M

EPS

-0.28

Gewinnspanne

-41.674

Angestellte

536

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+105.3 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

41M

990M

Vorheriger Eröffnungskurs

4.12

Vorheriger Schlusskurs

7.83

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

6.1 / 7.65 Unterstützung & Widerstand

BioCryst Pharmaceuticals Inc Chart

Ähnliche Nachrichten

26. Juli 2024, 22:06 UTC

Wichtige Markttreiber

vTv Therapeutics Shares Tumble After FDA Pauses Diabetes-Treatment Study

DJ

Lesen

26. Juli 2024, 19:26 UTC

Ergebnisse

Trending: 3M Shares Surge On Earnings

DJ

Lesen

26. Juli 2024, 17:40 UTC

Ergebnisse

Merck KGaA FY24 Outlook Improves After Strong Second Quarter

DJ

Lesen

26. Juli 2024, 17:21 UTC

Wichtige Markttreiber

Aon Shares Rise Following Better-Than-Expected 2Q Results

DJ

Lesen

26. Juli 2024, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Burger King Parent Company and More Stocks See Action From Activist Investors -- Barrons.com

DJ

Lesen

26. Juli 2024, 21:27 UTC

Market Talk

Consumers Are Skipping Starbucks' Half-Priced Drinks -- Market Talk

DJ

Lesen

26. Juli 2024, 20:54 UTC

Ergebnisse

3M Stock Had Its Best Day Ever. The New CEO Started With a Bang. -- Barrons.com

DJ

Lesen

26. Juli 2024, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

DJ

Lesen

26. Juli 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Lesen

26. Juli 2024, 20:50 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

DJ

Lesen

26. Juli 2024, 20:50 UTC

Top News

Dow Industrials Jump to Cap Volatile Week -- WSJ

DJ

Lesen

26. Juli 2024, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Real Estate, MRP Group Announce Extension of 100% Cash Tender Offer for Terrafina

DJ

Lesen

26. Juli 2024, 20:16 UTC

Ergebnisse

These Stocks Moved the Most Today: DexCom, 3M, Nvidia, Bristol Myers, Coursera, Biogen, Charter, Deckers, and More -- Barrons.com

DJ

Lesen

26. Juli 2024, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Fall for Second Straight Week -- Market Talk

DJ

Lesen

26. Juli 2024, 19:15 UTC

Market Talk

Oil Futures Close Lower for a Third Straight Week -- Market Talk

DJ

Lesen

26. Juli 2024, 19:00 UTC

Market Talk

Nike Must Restore Exclusivity to Jumpstart Footwear Brand -- Market Talk

DJ

Lesen

26. Juli 2024, 18:29 UTC

Market Talk

Gold Shares Attempt To Reverse Losses -- Market Talk

DJ

Lesen

26. Juli 2024, 17:36 UTC

Market Talk

U.S. Oil Rig Count Rises By Five To 482 -- Market Talk

DJ

Lesen

26. Juli 2024, 16:57 UTC

Ergebnisse

Merck KGaA to Post Full 2Q Figures as Scheduled on Aug 1

DJ

Lesen

26. Juli 2024, 16:55 UTC

Ergebnisse

Merck KGaA Sees 2024 EBITDA Before One-Time Items of Approx. EUR5.8B to EUR6.4B

DJ

Lesen

26. Juli 2024, 16:54 UTC

Ergebnisse

Merck KGaA Sees 2024 Net Sales of Approx. EUR20.7B to EUR22.1B

DJ

Lesen

26. Juli 2024, 16:54 UTC

Ergebnisse

Merck KGaA: Performance of Life Science Is Within Expectations

DJ

Lesen

26. Juli 2024, 16:54 UTC

Ergebnisse

Merck KGaA: Main Driver Is Very Strong Oper Performance of Healthcare, Electronics Compared to Consensus

DJ

Lesen

26. Juli 2024, 16:53 UTC

Ergebnisse

Merck KGaA 2Q EBITDA Before One-Time Items EUR1.51B

DJ

Lesen

26. Juli 2024, 16:52 UTC

Ergebnisse

Merck KGaA 2Q Net Sales EUR5.35B

DJ

Lesen

26. Juli 2024, 16:51 UTC

Ergebnisse

Intel's AI Chip Story 'Feels Mostly MIA,' Says Analyst -- Barrons.com

DJ

Lesen

26. Juli 2024, 16:51 UTC

Ergebnisse

Merck KGaA Raised Guidance for Fiscal 2024

DJ

Lesen

26. Juli 2024, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

DJ

Lesen

26. Juli 2024, 16:20 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

DJ

Lesen

26. Juli 2024, 16:20 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

DJ

Lesen

Peer-Vergleich

Kursveränderung

BioCryst Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

105.3% Vorteil

12-Monats-Prognose

Durchschnitt 15.5 USD  105.3%

Hoch 30 USD

Tief 6 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioCryst Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

7

Buy

1

Halten

0

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für BioCryst Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.1 / 7.65Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Mittelfristig

Strong Bullish Evidence

All events are bullish.

Langfristig

Strong Bearish Evidence

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

802.55

↓-2.25%

UNH

UnitedHealth Group Inc

569.62

↑ +1.64%

NVO

Novo Nordisk A-S

126.83

↓-0.63%

JNJ

Johnson and Johnson

160.55

↑ +0.48%

MRK

Merck & Co Inc.

125.13

↓-0.6%